Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: A new anti-BLyS human monoclonal antibody

Indian Journal of Dermatology, Venereology and Leprology

Volumn 80, Issue 5, 2014, Pages 477-478

  Husein Elahmed, Husein ^a   Callejas Rubio, Jose Luis ^a   Rios Fernandez, Raquel ^a   Ortego Centeno, Norberto ^a  

^a San Cecilio University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; HEMOGLOBIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; RO ANTIBODY; UREA; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CELL INFILTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; LETTER; LEUKOCYTE COUNT; MIDDLE AGED; MUSCULOSKELETAL DISEASE; MYALGIA; REFRACTORY SUBACUTE CUTANEOUS LUPUS ERYTHEMATOUS; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UREA BLOOD LEVEL; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; TREATMENT FAILURE;

EID: 84907553123     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.140335     Document Type: Letter

References (5)

1. Human Genome Sciences, Inc. Center for drug evaluation and research. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/125370Orig1s000Lbl.pdf. [Last accessed on 2011 Mar 29].
2. Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, et al. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006;65:545-8.
3. Kim SS, Kirou KA, Erkan D. Belimumab in systemic lupus erythematosus: An update for clinicians. Ther Adv Chronic Dis 2012;3:11-23.
4. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
5. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.